Positioning of advanced therapies in patients with moderate-to-severe Crohn's disease
Tian Yu Qiu1, Chin Kimg Tan1, Jeannie Peng Lan Ong1
1Department of Gastroenterology and Hepatology, Changi General Hospital, Singapore.
Abstract:
The treatment landscape for Crohn's disease (CD) has evolved substantially in the 21st century with the advent of advanced therapies. Since the introduction of tumour necrosis factor (TNF) antagonists, new classes of advanced CD therapies have been approved for use in the Asia-Pacific region, including anti-integrins, interleukin (IL)-12/23p40 inhibitors, IL-23p19 inhibitors and Janus kinase inhibitors (JAKi). In the last 10 years, biosimilars to infliximab, adalimumab and ustekinumab and generic JAKi have also become available. In this review, we discuss the indications for advanced therapies and whether certain classes of drugs are preferred for specific patient subsets. We also discuss the choice of first- and second-line agents for CD.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease III: Crohn's Disease
Drugs for Treatment of Ulcerative Colitis in IBD

